Trials / Completed
CompletedNCT00211159
OmegAD (Omega-3 and Alzheimer's Disease)
Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-blind Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 204 (planned)
- Sponsor
- Karolinska University Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EPAX 1050TG |
Timeline
- Start date
- 2000-12-01
- First posted
- 2005-09-21
- Last updated
- 2017-07-31
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00211159. Inclusion in this directory is not an endorsement.